Financial Daily from THE HINDU group of publications
Wednesday, Jun 29, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Industry & Economy - Healthcare Products
Marketing - Standards & Benchmarks


Clarity eludes sale of nutraceuticals in Maharashtra from July

P.T. Jyothi Datta

Mumbai , June 28

LACK of clarity and nutraceuticals seem to go hand-in-hand. First, there is ambiguity on whether nutraceuticals is a food or drug. And, now, there is confusion on whether nutraceutical products can sell in Maharashtra without a drug licence, come July.

With just two days to go, the State Government is believed to have "stayed" a directive from the Maharashtra Food and Drug Administration (FDA) asking manufacturers to get a drug licence if they wanted to make curative claims on nutraceutical products.

A Ministry official handling the issue confirmed the development and said that the order staying the FDA directive was to be issued later on Tuesday. However, a top FDA official told Business Line that he was not aware of the development.

These conflicting signals emerged after a meeting between the State Food and Drugs Minister, Mr Manohar Naik, FDA authorities and representatives of the Health foods And Dietary Supplements Association (HADSA).

Representatives of nutraceutical and drug companies, including Herbalife, Banner, Amway, USV, Ranbaxy, Nicholas Piramal and Wockhardt, met the Minister, said an industry representative who attended the meeting.

The State FDA's directive had been issued some months ago when Ranbaxy was asked to get a drug licence for its Revital, a nutritional supplement for mental and physical health.

The developments are being closely watched by authorities at the Centre, as nutraceuticals gets tossed around between the Ministries of Health and Food. At last count, nutraceuticals were to be brought under the purview of the proposed Integrated Food Bill.

A representative with a domestic drug said that "functional foods" or nutraceuticals should be classified as a food and not a drug. If the July directive were to be implemented an estimated Rs 500 crore of nutraceuticals business would have come to a halt, the representative claimed. However, the industry official admitted that there should be regulations governing the labelling and advertising of the product.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
Tirupur dyeing industry seeks Jayalalithaa help


Vigorous monsoon spell in North India
Some States unhappy with TFC's suggestion on market borrowing
`Outcome Budget' in July
Efficient govt is the key: PM
NDC `endorses' 10th Plan Mid-Term Appraisal
Central excise to operate help centre from KCCI premises
Pranab sees scope to boost defence business with US
NTC may develop gem, jewellery centre on Mumbai mill land
Govt asks IOC to seek second opinion on IBP merger swap ratio
ONGC to net Rs 1,400 cr thanks to hike in gas prices
Oil industry services declared public utility for 6 more months
GSPC gas may be ready for commercial usage by Dec '07
Monsoon eases power situation across AP
NGOs seek review of hydel power policy
Coal, Power Ministers to discuss thermal plants' problems today
Textile hub for Mahabubnagar
IL&FS keen on textile proposals
Cabinet to take up pvt FM radio policy
AP: Training in soft skills
Coaching classes for GATE
Learning programme
Jewellery market estimated at over Rs 58,000 cr: Survey
Real estate boom may help NTC fund revamp
Clarity eludes sale of nutraceuticals in Maharashtra from July
Tariff reduction formula only on bound rates, says Kamal Nath
Kerala to formulate bamboo policy
Direct taxes advisory panel revamped
Amul posts marginal topline growth, trebles its exports
ADB's extended tsunami mission from July 1
DGP to head Youth Hostels Assn of AP unit
SAS CEO named to WEF panel


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line